Amikin, Arikayce liposomal(amikacin)
Amikacin, Arikayce (amikacin) is a small molecule pharmaceutical. Amikacin was first approved as Amikin on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, burns, central nervous system infections, and endocarditis amongst others in the USA. It has been approved in Europe to treat respiratory tract infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Amikacin, Arikayce (discontinued: Amikacin, Amikin)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amikacin sulfate | ANDA | 2024-06-14 |
| amikacin sulfate injection, 500 mg/2ml | Export only | 2021-01-03 |
| arikayce | New Drug Application | 2025-03-17 |
Indications
FDA
EMA
Show 9 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AMIKACIN SULFATE, ARIKAYCE KIT, INSMED INC | |||
| 2030-09-28 | GAIN | ||
| 2025-09-28 | ODE-214 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Amikacin Sulfate, Arikayce Kit, Insmed Inc | |||
| 9895385 | 2035-05-15 | U-2417 | |
| 10251900 | 2035-05-15 | U-2414 | |
| 10751355 | 2035-05-15 | U-2414 | |
| 11446318 | 2035-05-15 | U-2414 | |
| 9566234 | 2034-01-18 | DP | U-2415 |
| 8226975 | 2028-08-15 | DP | |
| 8632804 | 2026-12-05 | U-2416 | |
| 8642075 | 2026-12-05 | DP | |
| 8679532 | 2026-12-05 | U-2415 | |
| 7718189 | 2025-06-06 | DP | U-2415 |
| 8802137 | 2024-04-08 | DP | U-2414 |
| 9827317 | 2024-04-08 | DP | U-2415 |
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX12: Amikacin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01G: Aminoglycoside antibacterials
— J01GB: Other aminoglycosides in atc
— J01GB06: Amikacin
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA06: Cefepime and amikacin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA21: Amikacin
HCPCS
Code | Description |
|---|---|
| J0278 | Injection, amikacin sulfate, 100 mg |
Clinical
Clinical Trials
127 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 2 | 5 | 9 | 6 | 8 | 28 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 11 | 6 | 5 | 7 | 27 |
| Communicable diseases | D003141 | — | — | 1 | 3 | 5 | 3 | 8 | 19 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 1 | 3 | 3 | 7 | 13 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 2 | 2 | 3 | 4 | 12 |
| Fibrosis | D005355 | — | — | 3 | 3 | 2 | 2 | 3 | 11 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 4 | 3 | 3 | 3 | 11 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | 1 | — | 2 | 5 | 9 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | 4 | 2 | 1 | 1 | 8 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 2 | 2 | 3 | 1 | 8 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 3 | 3 | 3 | — | 7 | 14 |
| Mycobacterium infections | D009164 | — | A31.9 | — | 5 | 5 | — | — | 9 |
| Nontuberculous mycobacterium infections | D009165 | EFO_0007461 | A31.9 | — | 3 | 4 | — | — | 7 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 6 | 1 | — | — | 7 |
| Septic shock | D012772 | — | A48.3 | — | — | 1 | — | 3 | 4 |
| Persistent infection | D000088562 | — | — | 2 | 2 | 1 | — | — | 4 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | — | 1 | 2 | — | — | 3 |
| Neonatal sepsis | D000071074 | — | — | — | — | 1 | — | 2 | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | 1 | — | 1 | 3 |
| Ototoxicity | D000081015 | — | — | — | 3 | 1 | — | — | 3 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 2 | 3 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | 2 | — | — | 1 | 3 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Urologic surgical procedures | D013520 | — | — | — | 1 | — | — | — | 1 |
| Nontuberculous mycobacteria | D009170 | — | — | — | 1 | — | — | — | 1 |
| Abdominal abscess | D018784 | EFO_1001753 | — | — | 1 | — | — | — | 1 |
| Extracorporeal membrane oxygenation | D015199 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | 2 | 6 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Obstructive lung diseases | D008173 | — | — | 1 | — | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | — | — | — | — | 1 |
| Necrotizing enterocolitis | D020345 | EFO_0003928 | K55.3 | 1 | — | — | — | — | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | 1 | — | — | — | — | 1 |
| Enterocolitis | D004760 | EFO_1001481 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 3 | 3 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 3 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Enterococcus | D016983 | — | — | — | — | — | — | 2 | 2 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 2 | 2 |
| Keratitis | D007634 | — | H16 | — | — | — | — | 2 | 2 |
| Chronic bronchitis | D029481 | — | J42 | — | — | — | — | 1 | 1 |
| Bronchitis | D001991 | — | J40 | — | — | — | — | 1 | 1 |
| Disease susceptibility | D004198 | — | — | — | — | — | — | 1 | 1 |
| Endophthalmitis | D009877 | — | — | — | — | — | — | 1 | 1 |
Show 71 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amikacin |
| INN | amikacin |
| Description | Amikacin is an amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group. It has a role as an antimicrobial agent, an antibacterial drug and a nephrotoxin. It is an alpha-D-glucoside, an aminoglycoside, a carboxamide and an amino cyclitol glycoside. It is functionally related to a kanamycin A. It is a conjugate base of an amikacin(4+). |
| Classification | Small molecule |
| Drug class | antibiotics obtained from Streptomyces kanamyceticus (related to kanamycin) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 37517-28-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL177 |
| ChEBI ID | 2637 |
| PubChem CID | 37768 |
| DrugBank | DB00479 |
| UNII ID | 84319SGC3C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 40,647 documents
View more details
Safety
Black-box Warning
Black-box warning for: Amikacin sulfate, Arikayce
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,251 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use